Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials-Reference-Cited by-同舟云学术

Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials

Published:2020-12-15 Issue:6 Volume:61 Page:810-819
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Dello Russo Cinzia¹,Cappoli Natalia¹,Pilunni Daniela²,Navarra Pierluigi¹^ORCID

Affiliation:

1. Department of Healthcare Surveillance and Bioethics Section of Pharmacology Università Cattolica del Sacro Cuore–Fondazione Policlinico Universitario A. Gemelli IRCCS Rome Italy

2. Postgraduate School of Hospital Pharmacy Sapienza University Rome Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1790

Reference39 articles.

1. A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials

2. Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis

3. Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?

4. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?

5. Real‐world evidence and randomized studies in the precision oncology era: the right balance [published online ahead of print October 30, 2017];Gyawali B;JCO Precision Oncology

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations;International Journal of Clinical Oncology;2024-08-27

2. RECIST 1.1 assessments variability: a systematic pictorial review of blinded double reads;Insights into Imaging;2024-08-07

3. Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials;JCO Precision Oncology;2024-02

4. Duration of and time to response in oncology clinical trials from the perspective of the estimand framework;Pharmaceutical Statistics;2023-10-02

5. Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study;BMJ Evidence-Based Medicine;2023-08-16